

**Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of The Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors,  
Venmax Drugs and Pharmaceuticals Limited

We have reviewed the accompanying Statement of unaudited financial results of Venmax Drugs and Pharmaceuticals Limited (the "Company") for the quarter and six months ended September 30, 2025 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the Listing Regulations").


This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG And CO  
Chartered Accountants  
FRN: 0009655S

  
GIRDHARI LAL TOSHNIWAL  
(Partner)  
M.No-205140



Udin No: 252051408MOPHN2938

Place: Hyderabad  
Date: 12/11/2025

VENMAX DRUGS AND PHARMACEUTICALS LIMITED  
Statement of Assets and Liabilities as at 30 th September 2025

Rs. In Lakhs

Particulars	Notes	As at 30th September 2025, Unaudited	As at 31 March 2025, Audited
<b>I. ASSETS</b>			
(1) Non Current Assets			
(a) Property, Plant and Equipment	3	3.85	4.05
(b) Capital Work-In-Progress			
(c) Intangible Assets			
(d) Financial Assets			
(i) Non-Current Investments			
(ii) Trade and Other Receivables			
(iii) Long Term Loans and Advances			
(d) Deferred Tax Assets (Net)			
(e) Other Non-Current Assets			
<b>Non-Current Assets</b>		<b>3.85</b>	<b>4.05</b>
(2) Current Assets			
(a) Inventories	4	152.90	5.75
(b) Financial Assets			
(i) Investments			
(ii) Trade and Other Receivables	5	347.12	95.26
(iii) Cash and Cash Equivalents	6	562.26	248.24
(iv) Short Term Loans and Advances	7	273.05	161.00
(c) Other Current Assets	8	25.50	2.67
<b>Current Assets</b>		<b>1360.83</b>	<b>512.91</b>
<b>Total Assets</b>		<b>1364.68</b>	<b>516.96</b>
<b>I. EQUITY AND LIABILITIES</b>			
(1) Equity			
(a) Share Capital	9	800.7933	523.89
(b) Other Equity	10	56.93	-82.70
<b>Equity</b>		<b>857.72</b>	<b>441.19</b>
(2) Non Current Liabilities			
(a) Financial Liabilities			
(i) Long Term Borrowings			
(b) Provisions			
(c) Deferred Tax Liabilities (Net)	11	0.10	0.10
(d) Other Non-current Liabilities			
<b>Non-Current Liabilities</b>		<b>0.10</b>	<b>0.10</b>
(3) Current Liabilities			
(a) Financial Liabilities			
- Short term Borrowings			
- Other Financial Liabilities			
(i) Trade Payables			
Micro and small enterprises			
Other than micro and small enterprises	13	188.41	62.87
(b) Short Term Provisions			
(c) Other Current Liabilities	14	7.76	7.84
<b>Current Liabilities</b>		<b>506.87</b>	<b>75.67</b>
<b>Total Liabilities</b>		<b>1364.69</b>	<b>516.96</b>

See accompanying notes to the financial statements 1-23


In terms of our attached report of even date

For PPKG AND CO'

CHARTERED ACCOUNTANTS

FRN No-096555

*Girdhari Lal Toshniwal*  
(PARTNER)  
M. NO. : 205140  
UDIN: 25205140BMOPHN2938



For Venmax Drugs & Pharmaceuticals Limited

DASI RAKESH REDDY  
Director  
DIN: 07112785



VENKATA RAO SADHANALA  
Director  
DIN No-02906370

Date - 12/11/2025  
Place - Hyderabad

**VENMAX DRUGS AND PHARMACEUTICALS LIMITED**  
**STATEMENT OF PROFIT AND LOSS FOR THE HALF YEAR ENDED 30th September 2025**

(Rs in Lakhs)

Particulars	Notes	As at 30th Sep 2025	As at 31st March 2025
		Unaudited	Audited
Revenue from operations	15	252.87	80.73
Other income	16	0.00	105.32
<b>Total Revenue</b>		<b>252.87</b>	<b>186.05</b>
<b>Expenses</b>			
Cost of materials consumed			
Purchases of Stock-in-Trade	17	370.66	85.21
Changes in inventories of finished goods		-147.15	-5.75
Employee benefits expense	18	10.77	4.04
Finance costs	19	0.08	0.08
Depreciation and amortization expense	20	0.20	0.64
Other expenses	21	10.06	103.24
<b>Total expenses</b>		<b>244.62</b>	<b>187.46</b>
Profit before exceptional, extraordinary and prior period items and tax		8.25	-1.41
Exceptional items			
Profit before extraordinary and prior period items and tax		8.25	-1.41
Extraordinary Items			
Profit before prior period items and tax		8.25	-1.41
Prior Period Items			
<b>Profit before tax</b>		<b>8.25</b>	<b>-1.41</b>
Tax expense:	22		
Current tax		2.08	-
Deferred tax		-0.00	-0.36
<b>Profit/(loss) for the period from continuing operations</b>		<b>6.18</b>	<b>-1.05</b>
Profit/(loss) from discontinuing operations			
Tax expense of discontinuing operations			
Profit/(loss) from Discontinuing operations (after tax)			
<b>Profit/(loss) for the period</b>		<b>6.18</b>	<b>-1.05</b>
Earnings per equity share:	23		
Basic		0.01	-0.02
Diluted		0.01	-0.02

See accompanying notes to the financial statements 1-23

In terms of our attached report of even date

For Venmax Drugs & Pharmaceuticals Limited

For PPKG AND CO  
 CHARTERED ACCOUNTANTS  
 FRN No-096555  
 GIRDHARI LAL TOSHIWAL  
 (PARTNER)  
 M. NO. : 205140



Place: Hyderabad  
 Date: 12/11/2025

D. Rakesh Reddy  
 DASI RAKESH REDDY  
 Director  
 DIN: 07112785



VENKATA RAO SADHANAL  
 (Director)  
 DIN No-02906370

Note 3

S.No	Description of Asset	Opening Date	Closing date	No of days	Gross Block 01/04/2025	Rate of Depreciation	Depreciation as on 30/09/2025	sale	30-09-2025	30/09/2025	Net Block as on 31/03/2025	Net Block as on 31/03/2025
1	Computers	01-04-2025	30-09-2025	183.00	0.002	31.67%	0.000				0.001	0.002
2	Computers	01-04-2025	30-09-2025	183.00	0.013	31.67%	0.002				0.011	0.013
3	Computers	01-04-2025	30-09-2025	183.00	0.006	31.67%	0.001				0.005	0.006
4	Computers	01-04-2025	30-09-2025	183.00	0.016	31.67%	0.003				0.013	0.016
5	Computers	01-04-2025	30-09-2025	183.00	0.019	31.67%	0.003				0.016	0.019
Sub Total					0.055		0.009				0.046	0.055
8	Furniture	01-04-2025	30-09-2025	183.00	3.992	9.50%	0.19				3.802	3.99
Total					3.99		0.19				3.80	3.99
Grand Total					4.047		0.1988901	0.000			3.848	4.05

NOTES ON ACCOUNTS FOR THE QUARTER ENDED 30 th SEPTEMBER 2025

4 Inventories

Particulars	30-09-2025	31-03-2025
Closing Stock	152.90	5.75
	<b>152.90</b>	<b>5.75</b>

5 Trade Receivables

Particulars	30-09-2025	31-03-2025
<b>Unsecured, Considered Good</b>		
Trade Receivables		
HATRI PHARMA PRIVATE LIMITED	0.00	0.00
Mora Pharma Private Limited	124.34	56.00
Chemgenix Laboratories Pvt Ltd	67.20	-
KMR LIFE SCIENCES	2.68	-
SATYADEVA ORGANOSYS PRIVATE LIMITED	152.90	-
	<b>347.12</b>	<b>56.00</b>

Ageing Schedule as at 30-09-2025

Particulars

	less than 6 months	6 months-1 year	1- 2 years	2- 3 years	Total
(i) Undisputed Trade receivables - considered good	347.12	-	-	-	347.12
(ii) Undisputed Trade Receivables - considered doubtful	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-

Ageing Schedule as at 31-03-2025

Particulars

	less than 6 months	6 months-1 year	1- 2 years	2- 3 years	Total
(i) Undisputed Trade receivables - considered good	95.26	-	-	-	95.26
(ii) Undisputed Trade Receivables - considered doubtful	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-

6 Cash and cash equivalents

Particulars	30-09-2025	31-03-2025
Cash in Hand	0.06	0.02
<b>Bank accounts</b>		
ICICI Bank Account No-630805161865	45.01	2.85
ICICI Share Application 2267	214.10	242.25
IDFC Bank-1010	303.10	3.11
IDBI bank account	0.00	0.01
	<b>562.26</b>	<b>248.24</b>

7 Short Term loans and Advances

Particulars	30-09-2025	31-03-2025
<b>Loans and Advances to Related parties</b>		
<b>Secured , considered good</b>		
Blue Nile Capital Advisory ltd	96.55	161.00
Blue Nile Current Account	311.00	-
Santha Ghosh	78.00	-
BSC Pre Paid Annual Listing Fees	1.63	-
VIDHATA LIFE SCIENCES PVT LTD	36.53	-
Vineet Life Sciences Private Limited	-250.64	-
	<b>273.05</b>	<b>161.00</b>

8 Other current assets

Particulars	30-09-2025	31-03-2025
Gst receivable	25.49	2.67
Deferred GST	0.01	-
	<b>25.50</b>	<b>2.67</b>

**9 Statement of changes in equity for the Half Year ended ended 30th September 2025**

**Equity Share Capital**

Particulars	30-09-2025	31-03-2025
Authorised		
2,20,00,000(80,00,000) Equity Shares Capital of Rs 10/- Par value	2200	2,200.00
	2200	2,200.00
Issued		
52,38,930(52,38,930) Equity Shares Capital of Rs. 10/- Par Value	523.89	523.89
24,15,667(24,15,667)(Equity Shares Capital of Rs. 10/- Par Value	241.57	
3,53,333(3,53,333)(Equity Shares Capital of Rs. 10/- Par Value	35.33	
Subscribed	800.79	523.89
52,38,930(52,38,930) Equity Shares Capital of Rs. 10/- Par Value	523.89	523.89
24,15,667(24,15,667)(Equity Shares Capital of Rs. 10/- Par Value	241.57	
3,53,333(3,53,333)(Equity Shares Capital of Rs. 10/- Par Value	35.33	
Paidup	800.79	523.89
52,38,930(52,38,930) Equity Shares Capital of Rs. 10/- Par Value	523.89	523.89
24,15,667(24,15,667)(Equity Shares Capital of Rs. 10/- Par Value	241.57	
3,53,333(3,53,333)(Equity Shares Capital of Rs. 10/- Par Value	35.33	
	800.79	523.89

**Holding More Than 5%**

Particulars	30-09-2025		31-03-2025	
	Number of Share	% Held	Number of Share	% Held
VENKAT NARENDER NUKA	9,26,775.00	17.69%	9,26,775.00	17.69%
PERCY HOMI ITALIA	4,66,161.00	8.90%	4,66,161.00	8.90%
RAJ KUMAR RAI	-	-	-	-
DR TADLA TIRUMAL RAO	2,84,900.00	5.44%	2,84,900.00	5.44%

**Reconciliation**

Particulars	30-09-2025		31-03-2025	
	Number of Share	Amount	Number of Share	Amount
Number of shares at the beginning	52,38,930.00	5,23,89,300.00	52,38,930.00	5,23,89,300.00
Add : Issue	27,69,000	2,76,90,000.00		
Shares issued				
Less : Bought Back				
Others				
Number of shares at the end	80,07,930.00	8,00,79,300.00	52,38,930.00	5,23,89,300.00

**10 Other Equity**

Particulars	30-09-2025	31-03-2025
Retained Earnings		
Profit and Loss Opening	-589.95	-588.89
Amount Transferred From Statement of P&L	6.18	-1.05
<b>Balance at the end of the period</b>	<b>-583.77</b>	<b>-589.94</b>
Securities Premium		
Balance at the beginning of the year	0	
Add: Received during the year	276.90	
Less: Utilised during the year	0	
<b>Balance at the end of the period</b>	<b>276.90</b>	<b>0.00</b>
Share application money pending allotment		
Opening Balance	507.25	
add: received during the year	490.20	507.25
less: Allotted during the year	628.65	
less: Refund during the year	5	
<b>Balance at the end of the period</b>	<b>363.80</b>	<b>507.25</b>
	56.93	-82.69

**11 Deferred Tax Asset**

Particulars	30-09-2025	31-03-2025
Deferred Tax Assets		
Property, Plant and Equipment	0.10	0.10
	<b>0.10</b>	<b>0.10</b>

**12 Short Term Borrowings**

Particulars	30-09-2025	31-03-2025
<b>Loans and advances from related parties</b>		
Sadhanala Venkata Rao	2.00	2.00
Somani Herbs and Agro Private Limited	2.96	2.96
HATRI PHARMA PRIVATE LIMITED	305.73	39.27
	<b>310.69</b>	<b>44.23</b>
		-266.46
		266.46255

**13 Trade Payables**

as at 30-09-2025

Particulars	Outstanding for following periods from due date of pay				Not Due	
	Less than 1 year	1-2 years	2-3 years	more than 3 years		
(i) MSME	-	-	-	-	-	-
(ii) Others	176.29	12.12	-	-	-	<b>188.41</b>
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-

as at 31-03-2025

Particulars	Outstanding for following periods from due date of pay				Not Due	Total
	Less than 1 year	1-2 years	2-3 years	more than 3 years		
(i) MSME	-	-	-	-	-	-
(ii) Others	55.06	7.81	-	-	-	<b>62.87</b>
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-

**14 Other Current Liabilities**

Particulars	30-09-2025	31-03-2025
<b>Other payables</b>		
Audit Fees payable	0.70	0.70
PF payable	0.62	0.62
Salaries payable	1.49	0.85
TDS payable	1.64	1.32
Rent payable	1.20	0.90
Electricity Payable	0.04	
Big shares Services pvt ltd	-	-
Blue Nile Capital Advisory Ltd	0.00	3.45
<b>Other Current Liabilities</b>		
Income Tax provision	2.08	-
	<b>7.76</b>	<b>7.84</b>

**15 Revenue from Operations**

Particulars	30-09-2025	31-03-2025
Revenue from operations	252.87	80.73
	<b>252.87</b>	<b>80.73</b>

**16 Other Income**

Particulars	30-09-2025	31-03-2025
Other Income	0.00	105.32
	<b>0.00</b>	<b>105.32</b>

**17 Purchases**

Particulars	30-09-2025	31-03-2025	Rs. In lakhs
Purchases	370.66	85.21	
	<b>370.66</b>	<b>85.21</b>	

**Changes in Inventories of Finished Goods, WIP and Stock In Trade**

Particulars	30-09-2025	31-03-2025	Rs. In lakhs
Opening Stock	5.75		
Closing stock	152.90	5.75	
Increase/Decrease	-147.15	-5.75	
	<b>-147.15</b>	<b>-5.75</b>	

**18 Employee benefits expense**

Particulars	30-09-2025	31-03-2025	Rs. In lakhs
Salary, Wages & Bonus			
Salary, Wages & Bonus	10.29	4.00	
Staff Welfare	0.48	0.04	
	<b>10.77</b>	<b>4.04</b>	

**19 Finance cost**

Particulars	30-09-2025	31-03-2025
Finance cost		
Bank charges	0.08	0.08
	<b>0.08</b>	<b>0.08</b>

**20 Depreciation and amortisation expense**

Particulars	30-09-2025	31-03-2025	Rs. In lakhs
Depreciation & Amortisation			
Depreciation on Tangible Assets	0.20	0.48	
	<b>0.20</b>	<b>0.48</b>	

**21 Other expenses**

Particulars	30-09-2025	31-03-2025	Rs. In lakhs
Administrative and General Expenses			
Telephone Postage		-	
TELEPHONE AND INTERNET	0.065	-	
Printing Stationery & Electricity		-	
ELECTRICITY	0.423	-	
PRINTING AND STATIONERY	0.379	-	
Auditors Remuneration			
AUDIT FEE	0.250	1.45	
Repairs Maintenance Expenses			
REPAIRS AND MAINTENANCE	0.015	0.04	

<b>Travelling Conveyance</b>			
TRAVELLING EXPENSES	0.000	0.17	
PORTER CHARGES			
<b>Legal and Professional Charges</b>			
PROFESSIONAL FEES	0.50	1.69	
LEGAL FEE	1.01	0.49	
<b>Other Administrative and General Expenses</b>			
OFFICE EXPENSES	0.49	0.16	
SALES PROMOTION			
RENT RATES AND TAXES	0.30	1.87	
<b>Other Expenses</b>			
OTHER EXPENSES	0.15	0.45	
Advertisement Exps	0.43	0.67	
Annual Listing Fees	1.63	23.27	
BSC EXPENSES	-	44.25	
ConvEYANCE Charges	0.07		
Consulting Charges	0.00		
CSDL ANNUAL FEES	1.24	1.00	
ROC EXPENSES	0.30	5.14	
RTA EXPENSES	0.92	0.98	
ESI FUND Account	1.68	6.96	
GST Late Fee	0.00	0.20	
Courier Charges	0.00		
Preferential issue expenses	0.00	12.60	
Donation	0.12		
Civil work	0.09		
Write off-Intangible asset	0	1.87	
Round off	0	0.00	
	<b>10.06</b>	<b>103.24</b>	

## 22 Tax expense

Particulars	Rs. In lakhs	
	30-09-2025	31-03-2025
Current tax		
CURRENT TAX	2.08	-
DEFERRED TAX ASSET	-0.00	-0.36
	<b>2.08</b>	<b>-0.36</b>

## 23 Earnings per equity share

Particulars	Rs. In lakhs	
	30-09-2025	31-03-2025
Earnings Per Equity Share		
Basic	0.01	0.02
Diluted	0.01	0.02
Number of Shares used in computing EPS		
Basic	800.79	52.39
Diluted	800.79	52.39
Weighted Average Number of shares		
Number of Shares for basic EPS calculation	800.79	52.39

In terms of our attached report of even date

For PPKG AND CO


CHARTERED ACCOUNTANTS

FRN No-096555

GIRDHARI LAL TOSHNIWAL

(PARTNER)

M. NO. : 205140



For Venmax Drugs & Pharmaceuticals Limited

DASI RAKESH REDDY

Director

DIN: 07112785

VENKATA RAO SADHANALA

Director

DIN No-02906370



Place : Hyderabad

Date : 12/11/2025